ERBB2 and breast carcinoma: Hence, in the current study, we examined whether YAP silencing affects the efficacy of trastuzumab in HER2-positive trastuzumab-sensitive and -resistant breast carcinoma cell lines, as well as in pathology specimens from patients with breast cancer.